Wednesday, January 29, 2014

The Motley Fool: Pfizer Inc. Treading Water Ahead Of Clinical Data

The Street almost seems to be processing the quarterly reports from Big Pharma companies like Bristol-Myers Squibb and Pfizer (NYSE: PFE  ) as annoying opening acts that just have to be tolerated before the headliner goes on stage. With that in mind, Pfizer's decent fourth quarter results aren't likely to matter as much as upcoming clinical trial results from studies of palbociclib ("palbo"), Prevnar, and Xeljanz that could collectively point the way toward over $10 billion in long-term revenue.

Continue reading here:
Pfizer Inc. Treading Water Ahead Of Clinical Data

No comments: